Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs104894226
rs104894226
0.710 GeneticVariation BEFREE One thymoma and one thymic carcinoma harbored KRAS mutations (G12A and G12V, respectively), and one thymoma had a G13V HRAS mutation. 19861435

2009

dbSNP: rs104894230
rs104894230
0.010 GeneticVariation BEFREE One thymoma and one thymic carcinoma harbored KRAS mutations (G12A and G12V, respectively), and one thymoma had a G13V HRAS mutation. 19861435

2009

dbSNP: rs112445441
rs112445441
0.010 GeneticVariation BEFREE One thymoma and one thymic carcinoma harbored KRAS mutations (G12A and G12V, respectively), and one thymoma had a G13V HRAS mutation. 19861435

2009

dbSNP: rs113488022
rs113488022
0.010 GeneticVariation BEFREE Activating kinase alterations discovered in BRAF V600E-wildtype Langerhans (LCH) and non-Langerhans cell histiocytoses (non-LCH) result in constitutive activation of the mitogen-activated protein kinase and/or phosphoinositide 3-kinases-Akt murine thymoma pathways. 27101528

2016

dbSNP: rs121434569
rs121434569
0.010 GeneticVariation BEFREE The PC-9-derived NSCLC cell lines PC-9ER and PC-9ZD, resistant to EGFR-TKI due to v-crk avian sarcoma virus CT10 oncogene homolog-like (CRKL) amplification-induced phosphatidylinositol 3-kinase (PI3K)/v-akt murine thymoma viral oncogene homolog (AKT) activation and an EGFR T790M mutation, respectively, were used. 24698130

2014

dbSNP: rs121913377
rs121913377
0.010 GeneticVariation BEFREE Activating kinase alterations discovered in BRAF V600E-wildtype Langerhans (LCH) and non-Langerhans cell histiocytoses (non-LCH) result in constitutive activation of the mitogen-activated protein kinase and/or phosphoinositide 3-kinases-Akt murine thymoma pathways. 27101528

2016

dbSNP: rs121913529
rs121913529
0.010 GeneticVariation BEFREE One thymoma and one thymic carcinoma harbored KRAS mutations (G12A and G12V, respectively), and one thymoma had a G13V HRAS mutation. 19861435

2009

dbSNP: rs1222380251
rs1222380251
0.010 GeneticVariation BEFREE Activating kinase alterations discovered in BRAF V600E-wildtype Langerhans (LCH) and non-Langerhans cell histiocytoses (non-LCH) result in constitutive activation of the mitogen-activated protein kinase and/or phosphoinositide 3-kinases-Akt murine thymoma pathways. 27101528

2016

dbSNP: rs1569686
rs1569686
0.010 GeneticVariation BEFREE In the present study we investigated if a common polymorphism (-579G>T: rs1569686) in the promoter of the DNMT3B gene coding for the DNA methyltransferase 3B, an enzyme that mediates DNA methylation, increases the risk to develop MG or MG-associated thymomas. 24260492

2013

dbSNP: rs2476601
rs2476601
0.010 GeneticVariation BEFREE DNA samples from 416 patients with clinically diagnosed generalized MG (231 with Abs to acetylcholine receptor, AChR-MG), 53 with Abs to muscle-specific kinase (MuSK-MG), 55 patients with no detectable Abs (SN-MG), 77 patients with thymoma (TAMG) and 293 healthy controls (HC) were genotyped for the SNP (PTPN22 R620W, C1858T, rs2476601). 25119822

2014

dbSNP: rs727503094
rs727503094
0.010 GeneticVariation BEFREE One thymoma and one thymic carcinoma harbored KRAS mutations (G12A and G12V, respectively), and one thymoma had a G13V HRAS mutation. 19861435

2009

dbSNP: rs77375493
rs77375493
0.010 GeneticVariation BEFREE This activity was coupled with inhibition of phosphorylation of the key JAK2(V617F)-dependent downstream signaling effectors signal transducer and activator of transcription (STAT)3, STAT5, and v-akt murine thymoma viral oncogene homolog (AKT). 18482053

2008

dbSNP: rs104894226
rs104894226
A 0.710 GeneticVariation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014

dbSNP: rs104894226
rs104894226
A 0.710 GeneticVariation CLINVAR Thymic tumors: relevant molecular data in the clinic. 20859122

2010

dbSNP: rs1057519701
rs1057519701
KIT
A 0.700 CausalMutation CLINVAR Large-scale analysis of KIT aberrations in Chinese patients with melanoma. 21325067

2011

dbSNP: rs1057519701
rs1057519701
KIT
A 0.700 CausalMutation CLINVAR Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. 22357254

2012

dbSNP: rs1057519704
rs1057519704
KIT
A 0.700 CausalMutation CLINVAR Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. 21969494

2011

dbSNP: rs1057519704
rs1057519704
KIT
A 0.700 CausalMutation CLINVAR Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. 22357254

2012

dbSNP: rs1057519704
rs1057519704
KIT
A 0.700 CausalMutation CLINVAR "When a thymic carcinoma ""becomes"" a GIST." 23375402

2013

dbSNP: rs1057519711
rs1057519711
KIT
A 0.700 CausalMutation CLINVAR Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. 22357254

2012

dbSNP: rs1057519711
rs1057519711
KIT
A 0.700 CausalMutation CLINVAR Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. 17699867

2007

dbSNP: rs1057519711
rs1057519711
KIT
A 0.700 CausalMutation CLINVAR Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. 19461405

2009

dbSNP: rs121913235
rs121913235
KIT
C 0.700 CausalMutation CLINVAR Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. 12960119

2003

dbSNP: rs121913235
rs121913235
KIT
C 0.700 CausalMutation CLINVAR Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. 22357254

2012

dbSNP: rs121913513
rs121913513
KIT
C 0.700 CausalMutation CLINVAR Mutational status of EGFR and KIT in thymoma and thymic carcinoma. 18448188

2008